Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 50, Issue 4, 2009, Pages 571-581

  Sáez, Ana I ^a   García Cosío, Mónica ^b   Sáez, Antonio J ^c   Hernández, Jesús M ^d   Sánchez Verde, Lidia ^e   Álvarez, David ^e   De La Cueva, Paloma ^e   Arranz, Reyes ^f   Conde, Eulogio ^g   Grande, Carlos ^h   Rodríguez, José ⁱ   Caballero, Dolores ^d   Piris, Miguel Á ^e  

^a Red de Bancos de Tumores de Andalucia   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c UNIVERSITY OF JAÉN   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e Centro Nacional de Investigaciones Oncológicas   (Spain)

^f HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^g HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Aggressive lymphoma; Prognostic factors; T cell immune response

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; BREAKPOINT CLUSTER REGION PROTEIN; CARMUSTINE; CD68 ANTIGEN; CD7 ANTIGEN; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DNA DIRECTED DNA POLYMERASE ALPHA; DNA PRIMASE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; MELPHALAN; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VINCRISTINE; XRCC1 PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER REGRESSION; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION PROFILING; GENE FUNCTION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOCYTIC INFILTRATION; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TISSUE MICROARRAY; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY; TISSUE ARRAY ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 68449093185     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902785528     Document Type: Article

References (33)

1. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000;18:3025-3030.
2. Bouabdallah R, Coso D, Costello R, Bardou VJ, Blaise D, Xerri L, et al. Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin's lymphoma: A retrospective series on 126 patients from a single center. Bone Marrow Transplant 2000;25:35-40.
3. Gianni AM, Bregni M, Siena S, Brambilla C, M. Di Nicola, Lombardi F, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997;336:1290-1297.
4. Veelken H, Vik Dannheim S, Schulte Moenting J, Martens UM, Finke J, Schmitt-Graeff A. Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy. Ann Oncol 2007;18:931-939.
5. Dalton WS, Friend SH. Cancer biomarkers - an invitation to the table. Science 2006;312:1165-1168.
6. Winter JN,Weller EA, Horning SJ, Krajewska M, Variakojis D, Habermann TM, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: A prospective correlative study. Blood 2006;107:4207-4213.
7. Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood 2003;101:1220-1235.
8. de Jong D, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications - a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007;25:805-812.
9. Arranz R, Conde E, Grande C, Mateos MV, Gandarillas M, Albo C, et al. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: A prospective study from the GELTAMO Study Group. Eur J Haematol 2008;80:227-235.
10. Jaffe ES, World Health Organization. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumors, Vol. 3. Lyon, Oxford: IARC Press, Oxford University Press (distributor); 2001. p 351.
11. Tracey L, Villuendas R, Ortiz P, Dopazo A, Spiteri I, Lombardia L, et al. Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma. Am J Pathol 2002;161:1825-1837.
12. Sanchez-Aguilera A, Montalban C, de la Cueva P, Sanchez- Verde L, Morente MM, Garcia-Cosio M, et al. Tumor micro-environment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006;108:662-668.
13. Vaquerizas JM, Dopazo J, Diaz-Uriarte R. DNMAD: Web-based diagnosis and normalization for microarray data. Bioinformatics 2004;20:3656-3658.
14. Montanan D, Tarraga J, Huerta-Cepas J, Burguet J, Vaquerizas JM, Conde L, et al. Next station in microarray data analysis: GEPAS. Nucleic Acids Res 2006;34(Web Server issue):W486-W491.
15. Rodriguez A, Villuendas R, Yanez L, Gomez ME, Diaz R, Pollan M, et al. Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: Clinical correlation. Leukemia 2007;21:1984-1991.
16. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159-2169.
17. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;98:5116-5121.
18. Gutierrez NC, Lopez-Perez R, Hernandez JM, Isidro I, Gonzalez B, Delgado M, et al. Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia 2005;19: 402-409.
19. Herrero J, Al-Shahrour F, Diaz-Uriarte R, Mateos A, Vaquerizas JM, Santoyo J, et al. GEPAS: A web-based resource for microarray gene expression data analysis. Nucleic Acids Res 2003;31:3461-3467.
20. Saez AI, Saez AJ, Artiga MJ, Perez-Rosado A, Camacho FI, Diez A, et al. Building an outcome predictor model for diffuse large B-cell lymphoma. Am J Pathol 2004;164:613-622.
21. Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G, et al. High numbers of tumor-infiltrating FOXP3- positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006;108:2957-2964.
22. D.C.T. R. R: A language and environment for statistical computing. Austria: V. R Foundation for Statistical Computing, Editor; 2007.
23. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
24. Colomo L, Lopez-Guillermo A, Perales M, Rives S, Martinez A, Bosch F, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003;101:78-84.
25. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005;105:1851-1861.
26. Hasselblom S, Sigurdadottir M, Hansson U, Nilsson-Ehle H, Ridell B, Andersson PO. The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma. Br J Haematol 2007;137:364-373.
27. Alvaro T, Lejeune M, Salvado MT, Bosch R, Garcia JF, Jaen J, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005;11:1467-1473.
28. Lee AM, Clear AJ, Calaminici M, Davies AJ, Jordan S, MacDougall F, et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006;24:5052-5059.
29. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008;93:193-200.
30. Lee NR, Song EK, Jang KY, Choi HN, Moon WS, Kwon K, et al. Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma 2008;49:247-256.
31. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949.
32. Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM. Intratumoral CD4+ CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+T cells in B-cell non-Hodgkin lymphoma. Blood 2006;107:3639-3646.
33. van Imhoff GW, Boerma EJ, van der Holt B, Schuuring E, Verdonck LF, Kluin-Nelemans HC, et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006;24:4135-4142.